Table 2.
Cumulative incidence of TEAEs in the safety population by study week in the extension, open-label, long-term safety study [20]
| Donepezil 23/23 mg (n = 570) |
Donepezil 10/23 mg (n = 332) |
|||||||
|---|---|---|---|---|---|---|---|---|
| 1 week | 2 weeks | 4 weeks | 52 weeks | 1 week | 2 weeks | 4 weeks | 52 weeks | |
| Patients with at least 1 TEAE | 15.8 | 18.6 | 23.2 | 72.8 | 20.8 | 25.9 | 31.9 | 78 |
| Patients who discontinued due to TEAEs Patients with TEAEs | 0.5 | 1.6 | 2.3 | 11.4 | 2.4 | 3.9 | 4.8 | 17.5 |
| Diarrhea | 0.4 | 0.4 | 0.9 | 3.5 | 1.5 | 2.1 | 2.7 | 5.7 |
| Nausea | 0.2 | 0.2 | 0.2 | 2.1 | 3.9 | 4.2 | 4.2 | 6 |
| Vomiting | 0 | 0 | 0 | 1.6 | 2.4 | 2.4 | 2.7 | 4.5 |
| Dizziness | 0.4 | 0.4 | 0.5 | 1.1 | 0.9 | 1.2 | 1.5 | 3.6 |
Values are percentages. Reprinted from Tariot et al. [20] (Copyright© Tariot et al.; licensee BioMed Central Ltd., 2012).